REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
17 avr. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Regeneron...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
11 avr. 2024 13h15 HE
|
Schall Law
The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
22 mars 2024 13h20 HE
|
KUEHN LAW, PLLC
Kuehn Law investigates potential breach of fiduciary duties by Regeneron Pharmaceuticals officers and directors. Shareholders urged to contact for details.
Regeneron Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
25 juil. 2023 15h04 HE
|
Block & Leviton LLP
BOSTON, July 25, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for potential securities law violations. Investors who have lost money...
REGN Shareholder News: Johnson Fistel Encourages Regeneron Pharmaceuticals Shareholders with Losses to Contact the Firm Regarding Investigation
30 juin 2023 14h49 HE
|
Johnson Fistel, LLP
SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the...
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
28 juin 2021 08h30 HE
|
Dyadic International, Inc.
Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1 -cell platform expressed SBV antigen exhibited efficacy, potency, and...
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
31 août 2020 20h54 HE
|
Bragar Eagel & Squire
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regeneron, Inc. (NASDAQ:...
SHAREHOLDER ALERT: Lowey Dannenberg Is Investigating Regeneron Pharmaceuticals, Inc. (REGN) for Potential Breaches of Fiduciary Duty by Its Board of Directors
20 août 2020 12h37 HE
|
Lowey Dannenberg, P.C.
NEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating a potential breach of fiduciary duty claim...
Scott+Scott Attorneys at Law LLP Investigates Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty – REGN
01 juil. 2020 11h27 HE
|
Scott+Scott Attorneys at Law LLP
NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is investigating whether certain directors...
Earth Science Tech Announces the Development of 3 New Advanced Formulated Cannabis CBD Nutraceuticals and 2 Cannabis CBD-Based Pharmaceutical Drugs under its Cannabis CBD Patent, IP and Technology
20 déc. 2016 07h45 HE
|
Earth Science Tech, Inc.
Ft. Lauderdale, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company focused on Cannabis (industrial hemp) Cannabinoid...